Abstract
Nerve growth factor and its high-affinity receptor TrkA are thought to be involved in the progression of various cancers. This study investigated the mechanism that regulates aberrant or increased TrkA expression in various cancer cell lines and in the course of pancreatic cancer progression. We found that the negative cis-acting AP-1-like sequence TGAGCGA was located in the 5′-untranslated region of the TrkA gene. Sodium bisulfite mapping revealed that steady-state TrkA expression correlated positively with the accumulation of methylated CpG around the AP-1-like site. Electrophoretic mobility shift assay showed that the AP-1-like site was bound mainly by c-Jun homodimers; the binding was directly blocked by Sss I methylase-induced methylation or by an excess of oligonucleotides containing consensus AP-1 sequences. Consequently, activation of TrkA gene expression by methylation was considered to be caused by the direct interference of c-Jun binding to the negatively regulating AP-1-like site. Furthermore, the accumulation of methylated CpG around the AP-1-like site was also observed with increased TrkA immunohistochemical staining in cases of advanced pancreatic adenocarcinoma with extensive perineural invasion. Unlike global methylation at CpG islands that leads to gene silencing, specific methylation at non-CpG islands would play a crucial epigenetic role in the versatility and plasticity of TrkA expression during cancer progression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Attwooll C, Denchi EL and Helin K . (2004). EMBO J., 23, 4709–4716.
Barrett GL . (2000). Prog. Neurobiol., 61, 205–229.
Bird AP and Wolffe AP . (1999). Cell, 99, 451–454.
Bockman DE, Buchler M and Beger HG . (1994). Gastroenterology, 107, 219–230.
Bothwell M . (1995). Annu. Rev. Neurosci., 18, 223–253.
Brellier F, Marionnet C, Chevallier-Lagente O, Toftgard R, Mauviel A, Sarasin A and Magnaldo T . (2004). Cancer Res., 64, 2699–2704.
Campanero M, Armstrong MI and Flemington K . (2000). Proc. Natl. Acad. Sci. USA, 97, 6481–6486.
Clark SJ and Melki J . (2002). Oncogene, 21, 5380–5387.
Descamps S, Toillon RA, Adriaenssens E, Pawlowski V, Cool SM, Nurcombe V, Le Bourhis X, Boilly B, Peyrat JP and Hondermarck H . (2001). J. Biol. Chem., 276, 17864–17870.
Eberhart CG, Kaufman WE, Tihan T and Burger PC . (2001). J. Neuropathol. Exp. Neurol., 60, 462–469.
Eden S, Constancia M, Hashimshony T, Dean W, Goldstein B, Johnson AC, Keshet I, Reik W and Cedar H . (2001). EMBO J., 20, 3518–3525.
Ehrlich M . (2002). Oncogene, 21, 5400–5413.
Esteller M, Corn PG, Baylin SB and Herman JG . (2001). Cancer Res., 61, 3225–3229.
Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL and Paul CL . (1992). Proc. Natl. Acad. Sci. USA, 89, 1827–1831.
George DJ, Suzuki H, Bova GS and Isaacs JT . (1998). Prostate, 36, 172–180.
Hempstead BL, Martin-Zanca D, Kaplan DR, Parada LF and Chao MV . (1991). Nature, 350, 678–683.
Indo Y, Mardy S, Tsuruta M, Karim MA and Matsuda I . (1997). Jpn. J. Hum. Genet., 42, 343–351.
Jones PA and Laird PW . (1999). Nat. Genet., 21, 163–167.
Kitazawa S, Kitazawa R and Maeda S . (1999). J. Biol. Chem., 274, 28787–28793.
Kitazawa S, Kitazawa R and Maeda S . (2000). Lab. Invest., 80, 275–276.
Kondo T, Kitazawa R, Maeda S and Kitazawa S . (2004). J. Bone Miner. Res., 19, 1411–1419.
Miknyoczki SJ, Lang D, Huang L, Klein-Szanto AJ, Dionne CA and Ruggeri BA . (1999). Int. J. Cancer, 81, 417–427.
Nakagawara A, Arima M, Azar CG, Scavarda NJ and Brodeur GM . (1992). Cancer Res., 52, 1364–1368.
Olek A, Oswald J and Walter J . (1996). Nucleic Acids Res., 24, 5064–5066.
Razin A and Cedar H . (1991). Microbiol. Rev., 55, 451–458.
Ricci A, Felici L, Mariotta S, Mannino F, Schmid G, Terzano C, Cardillo G, Amenta F and Bronzetti E . (2004). Am. J. Resp. Cell Mol. Biol., 30, 12–19.
Sakamoto Y, Kitajima Y, Edakuni G, Sasatomi E, Mori M, Kitahara K and Miyazaki K . (2001). Oncol. Rep., 8, 477–484.
Schneider MB, Standop J, Ulrich A, Wittel U, Friess H, Andren-Sandberg A and Pour PM . (2001). J. Histochem. Cytochem., 49, 1205–1210.
Suzuki T, Bogenmann E, Shimada H, Stram D and Seeger RC . (1993). J. Natl. Cancer Inst., 85, 377–384.
Tulchinsky EM, Georgiev GP and Lukanidin EM . (1996). Oncogene, 12, 1737–1745.
Wade PA . (2001). BioEssays, 23, 1131–1137.
Yi SQ, Miwa K, Ohta T, Kayahara M, Kitagawa H, Tanaka A, Shimokawa T, Akita K and Tanaka S . (2003). Pancreas, 27, 225–229.
Zhang XY, Ehrlich KC, Wang RY and Ehrlich M . (1986). Nucleic Acids Res., 14, 8387–8397.
Zhu WG, Srinivasan K, Dai Z, Duan W, Druhan LJ, Ding H, Yee L, Villalona-Calero MA, Plass C and Otterson GA . (2003). Mol. Cell. Biol., 23, 4056–4065.
Zhu Z, Friess H, diMola FF, Zimmermann A, Graber HU, Korc M and Buchler MW . (1999). J. Clin. Oncol., 17, 2419–2428.
Zhu Z, Kleeff J, Kayed H, Wang L, Korc M, Buchler MW and Friess H . (2002). Mol. Carcinog., 35, 138–147.
Acknowledgements
We thank Dr Luis F Parada (Center for Developmental Biology, UT Southwestern Medical Center) and Dr Yasuhiro Indo (Department of Pediatrics, Kumamoto University School of Medicine, Japan) for kindly providing TrkA cDNA. We also thank Dr Ushijima (Carcinogenesis Division, National Cancer Center Research Institute) for helpful suggestions. We thank Shuichi Matsuda for excellent technical assistance. This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Health and Welfare, Japan (to SK) and by a Grant-in-Aid for Scientific Research (to SK, No. 16590278, and to RK, No. 16590313), and for 21st Century COE Program, ‘Center of Excellence for Signal Transduction Disease: Diabetes Mellitus as Model’ from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fujimoto, M., Kitazawa, R., Maeda, S. et al. Methylation adjacent to negatively regulating AP-1 site reactivates TrkA gene expression during cancer progression. Oncogene 24, 5108–5118 (2005). https://doi.org/10.1038/sj.onc.1208697
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208697
Keywords
This article is cited by
-
DNA methylation alterations at RE1-silencing transcription factor binding sites and their flanking regions in cancer
Clinical Epigenetics (2023)
-
Identification and characterization of methylation-mediated transcriptional dysregulation dictate methylation roles in preeclampsia
Human Genomics (2020)
-
RETRACTED ARTICLE: Methylation and Expression Patterns of Tropomyosin-Related Kinase Genes in Different Grades of Glioma
NeuroMolecular Medicine (2014)
-
Inhibition of IFN-γ transcription by site-specific methylation during T helper cell development
The EMBO Journal (2006)